Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
April 01, 2021 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, April 01, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs
February 17, 2021 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
November 30, 2020 14:47 ET
|
Excision BioTherapeutics
San Francisco, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV –...
CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer
November 03, 2020 09:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapeutics to cure viral infectious diseases, announced today the...
Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer
August 04, 2020 12:00 ET
|
Excision BioTherapeutics
San Francisco, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a biotechnology company dedicated to curing viral infectious disease using CRISPR, today announced the appointment of TJ...
Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
March 11, 2020 15:27 ET
|
Excision BioTherapeutics
OAKLAND, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a private biotechnology company focused on applying CRISPR gene editing to curing viral infectious diseases, today...
CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.
December 03, 2019 12:30 ET
|
Excision BioTherapeutics
Oakland, CA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that...
Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
November 21, 2019 12:00 ET
|
Excision BioTherapeutics
Oakland, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- On November 20 at the 6th Annual Personalized Nanomedicine Symposium, researchers working with Excision BioTherapeutics, a gene therapy company...
CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure
November 18, 2019 12:00 ET
|
Excision BioTherapeutics
Oakland, CA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- At the 2019 International Symposium on Neurovirology, Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases,...
HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development
July 02, 2019 11:16 ET
|
Excision BioTherapeutics
Philadelphia, July 02, 2019 (GLOBE NEWSWIRE) -- Researchers at the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) have for the first time in...